VJVirtual | MRx0518 modification of solid tumor microenvironment

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, describes the formulation and observed immunostimulatory effects of MRx0518. This treatment represents a novel class of live biotherapeutic products derived from the microbiome. As a bacterium, it is administered in a lyophilized, encapsulated form. Once ingested, MRx0518 elicits a strong pro-inflammatory response in the innate immune system and locally in intestinal epithelial cells. Key biomarkers of various tumor types were analyzed post monotherapy with MRx0518 in the MICROBIOME study (NCT03934827) where it was demonstrated that treatment results in alterations to tumor microenvironment consistent with immune system stimulation. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).